Immune intervention in type 1 diabetes

Seminars in Immunology

Volumn 23, Issue 3, 2011, Pages 214-219

  Michels, Aaron W ^a   Eisenbarth, George S ^a  

^a UNIVERSITY OF COLORADO DENVER   (United States)

Author keywords

Autoantibodies; Immunotherapy; T cells; Tolerance; Type 1 diabetes

Indexed keywords

CD3 ANTIGEN; CYCLOPHOSPHAMIDE; CYCLOSPORIN A; GLUTAMATE DECARBOXYLASE 65; INSULIN; INTERLEUKIN 10; PREDNISONE; RECOMBINANT INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; RITUXIMAB; THYMOCYTE ANTIBODY; TRANSFORMING GROWTH FACTOR BETA;

AUTOIMMUNITY; B LYMPHOCYTE; CD8+ T LYMPHOCYTE; DIABETIC PATIENT; GENETIC VARIABILITY; HUMAN; IMMUNE RESPONSE; IMMUNOTHERAPY; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN RESISTANCE; NONHUMAN; PHASE 2 CLINICAL TRIAL (TOPIC); POST HOC ANALYSIS; REVIEW; T LYMPHOCYTE;

ANIMALS; ANTIGENS; AUTOIMMUNITY; DIABETES MELLITUS, TYPE 1; DIETARY PROTEINS; HUMANS; IMMUNE TOLERANCE; IMMUNOSUPPRESSION;

EID: 80052908633     PISSN: 10445323     EISSN: 10963618     Source Type: Journal    
DOI: 10.1016/j.smim.2011.07.003     Document Type: Review

References (81)

1. Eisenbarth G.S. Banting lecture 2009: an unfinished journey: molecular pathogenesis to prevention of Type 1A diabetes. Diabetes 2010, 59(4):759-774.
2. Bluestone J.A., Herold K., Eisenbarth G. Genetics: pathogenesis and clinical interventions in type 1 diabetes. Nature 2010, 464(7293):1293-1300.
3. Maahs D.M., Rewers M. Editorial Mortality and renal disease in type 1 diabetes mellitus-progress made: more to be done. J Clin Endocrinol Metab 2006, 91(10):3757-3759.
4. Steffes M.W., Sibley S., Jackson M., Thomas W. Beta-cell function and the development of diabetes-related complications in the diabetes control and complications trial. Diabetes Care 2003, 26(3):832-836.
5. Harjutsalo V., Sjoberg L., Tuomilehto J. Time trends in the incidence of type 1 diabetes in Finnish children: a cohort study. Lancet 2008, 371(9626):1777-1782.
6. Patterson C.C., Dahlquist G.G., Gyurus E., Green A., Soltesz G. Incidence trends for childhood type 1 diabetes in Europe during 1989-2003 and predicted new cases 2005-20: a multicentre prospective registration study. Lancet 2009, 373(9680):2027-2033.
7. Eisenbarth G.S. Type I diabetes mellitus. A chronic autoimmune disease. N Engl J Med 1986, 314:1360-1368.
8. Srikanta S., Ganda O.P., Gleason R.E., Jackson R.A., Soeldner J.S., Eisenbarth G.S. Pre-type I diabetes. Linear loss of beta cell response to intravenous glucose. Diabetes 1984, 33(8):717-720.
9. Sosenko J.M., Krischer J.P., Palmer J.P., Mahon J., Cowie C., Greenbaum C.J., et al. A risk score for type 1 diabetes derived from autoantibody-positive participants in the diabetes prevention trial-type 1. Diabetes Care 2008, 31(3):528-533.
10. Sosenko J.M., Palmer J.P., Rafkin L.E., Krischer J.P., Cuthbertson D., Greenbaum C.J., et al. Trends of earlier and later responses of C-peptide to oral glucose challenges with progression to type 1 diabetes in diabetes prevention trial-type 1 participants. Diabetes Care 2010, 33(3):620-625.
11. Wenzlau J.M., Juhl K., Yu L., Moua O., Sarkar S.A., Gottlieb P., et al. The cation efflux transporter ZnT8 (Slc30A8) is a major autoantigen in human type 1 diabetes. Proc Natl Acad Sci U S A 2007, 104(43):17040-17045.
12. Sherr J., Sosenko J., Skyler J.S., Herold K.C. Prevention of type 1 diabetes: the time has come. Nat Clin Pract Endocrinol Metab 2008.
13. Achenbach P., Bonifacio E., Ziegler A.G. Predicting type 1 diabetes. Curr Diab Rep 2005, 5(2):98-103.
14. Effects of age, duration and treatment of insulin-dependent diabetes mellitus on residual beta-cell function: observations during eligibility testing for the Diabetes Control and Complications Trial (DCCT). J Clin Endocrinol Metab 1987, 65(1):30-36. The DCCT Research Group.
15. Grajwer L.A., Pildes R.S., Horwitz D.L., Rubenstein A.H. Control of juvenile diabetes mellitus and its relationship to endogenous insulin secretion as measured by C-peptide immunoreactivity. J Pediatr 1977, 90(1):42-48.
16. Madsbad S., Faber O.K., Binder C., McNair P., Christiansen C., Transbol I. Prevalence of residual beta-cell function in insulin-dependent diabetics in relation to age at onset and duration of diabetes. Diabetes 1978, 27(Suppl. 1):262-264.
17. O'Meara N.M., Sturis J., Herold K.C., Ostrega D.M., Polonsky K.S. Alterations in the patterns of insulin secretion before and after diagnosis of IDDM. Diabetes Care 1995, 18(4):568-571.
18. Effect of intensive therapy on residual beta-cell function in patients with type 1 diabetes in the diabetes control and complications trial. A randomized, controlled trial. Ann Intern Med 1998, 128(7):517-523. The Diabetes Control and Complications Trial Research Group.
19. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. New Engl J Med 1993, 329:977-986. The Diabetes Control and Complications Trial Research Group.
20. Keenan H.A., Sun J.K., Levine J., Doria A., Aiello L.P., Eisenbarth G., et al. Residual insulin production and pancreatic ss-cell turnover after 50 years of diabetes: Joslin Medalist Study. Diabetes 2010, 59(11):2846-2853.
21. Foulis A.K., Stewart J.A. The pancreas in recent-onset type 1 (insulin-dependent) diabetes mellitus: insulin content of islets, insulitis and associated changes in the exocrine acinar tissue. Diabetologia 1984, 26(6):456-461.
22. Gianani R., Campbell-Thompson M., Sarkar S.A., Wasserfall C., Pugliese A., Solis J.M., et al. Dimorphic histopathology of long-standing childhood-onset diabetes. Diabetologia 2010, 53(4):690-698.
23. Gepts W. The pathology of the pancreas in human diabetes. Immunology in diabetes 1984, 21-35. Kimpton Medical Publications, London. D. Andreani, U. DiMario, K.F. Federlin, L.G. Heding (Eds.).
24. Harris P.E., Ferrara C., Barba P., Polito T., Freeby M., Maffei A. VMAT2 gene expression and function as it applies to imaging beta-cell mass. J Mol Med 2008, 86(1):5-16.
25. Medarova Z., Tsai S., Evgenov N., Santamaria P., Moore A. In vivo imaging of a diabetogenic CD8+ T cell response during type 1 diabetes progression. Magn Reson Med 2008, 59(4):712-720.
26. Gaglia J.L., Guimaraes A.R., Harisinghani M., Turvey S.E., Jackson R., Benoist C., et al. Noninvasive imaging of pancreatic islet inflammation in type 1A diabetes patients. J Clin Invest 2011, 121(1):442-445.
27. Feutren G., Assan G., Karsenty G., DuRostu H., Sirmai J., Papoz L., et al. Cyclosporin increases the rate and length of remissions in insulin dependent diabetes of recent onset. Results of a multicentre double-blind trial. Lancet 1986, 2(8499):119-124.
28. Stiller C.R., Dupre J., Gent M., Jenner M.R., Keown P.A., Laupacis A., et al. Effects of cyclosporine immunosuppression in insulin-dependent diabetes mellitus of recent onset. Science 1984, 223(4643):1362-1367.
29. Bougneres P.F., Carel J.C., Castano L., Boitard C., Gardin J.P., Landais P., et al. Factors associated with early remission of type I diabetes in children treated with cyclosporine. N Engl J Med 1988, 318(11):663-670.
30. Eisenbarth G.S., Srikanta S., Jackson R., Rabinowe S., Dolinar R., Aoki T., et al. Anti-thymocyte globulin and prednisone immunotherapy of recent onset type I diabetes mellitus. Diabetes Res 1985, 2(6):271-276.
31. Chatenoud L., Thervet E., Primo J., Bach J.F. Anti-CD3 antibody induces long-term remission of overt autoimmunity in nonobese diabetic mice. Proc Natl Acad Sci USA 1994, 91(1):123-127.
32. Chatenoud L., Bach J.F., Regulatory T cells in the control of autoimmune diabetes: the case of the NOD mouse. Int Rev Immunol 2005, 24(3-4):247-267.
33. Herold K.C., Hagopian W., Auger J.A., Poumian-Ruiz E., Taylor L., Donaldson D., et al. Anti-CD3 monoclonal antibody in new-onset type 1 diabetes mellitus. N Engl J Med 2002, 346(22):1692-1698.
34. Herold K.C., Gitelman S.E., Masharani U., Hagopian W., Bisikirska B., Donaldson D., et al. A Single course of Anti-CD3 monoclonal antibody hOKT3{gamma}1(Ala-Ala) results in improvement in C-peptide responses and clinical parameters for at least 2 years after onset of type 1 diabetes. Diabetes 2005, 54(6):1763-1769.
35. Herold K.C., Gitelman S., Greenbaum C., Puck J., Hagopian W., Gottlieb P., et al. Treatment of patients with new onset Type 1 diabetes with a single course of anti-CD3 mAb Teplizumab preserves insulin production for up to 5 years. Clin Immunol 2009, 132(2):166-173.
36. Keymeulen B., Vandemeulebroucke E., Ziegler A.G., Mathieu C., Kaufman L., Hale G., et al. Insulin needs after CD3-antibody therapy in new-onset type 1 diabetes. N Engl J Med 2005, 352(25):2598-2608.
37. Keymeulen B., Walter M., Mathieu C., Kaufman L., Gorus F., Hilbrands R., et al. Four-year metabolic outcome of a randomised controlled CD3-antibody trial in recent-onset type 1 diabetic patients depends on their age and baseline residual beta cell mass. Diabetologia 2010.
38. Keymeulen B., Candon S., Fafi-Kremer S., Ziegler A., Leruez-Ville M., Mathieu C., et al. Transient Epstein-Barr virus reactivation in CD3 monoclonal antibody-treated patients. Blood 2010, 115(6):1145-1155.
39. Belghith M., Bluestone J.A., Barriot S., Megret J., Bach J.F., Chatenoud L. TGF-beta-dependent mechanisms mediate restoration of self-tolerance induced by antibodies to CD3 in overt autoimmune diabetes. Nat Med 2003, 9(9):1202-1208.
40. Chatenoud L. CD3 antibody treatment stimulates the functional capability of regulatory T cells. Novartis Found Symp 2003, 252:279-286.
41. Herold K.C., Burton J.B., Francois F., Poumian-Ruiz E., Glandt M., Bluestone J.A. Activation of human T cells by FcR nonbinding anti-CD3 mAb: hOKT3gamma1(Ala-Ala). J Clin Invest 2003, 111(3):409-418.
42. Chatenoud L., Bluestone J.A. CD3-specific antibodies: a portal to the treatment of autoimmunity. Nat Rev Immunol 2007, 7(8):622-632.
43. Bisikirska B., Colgan J., Luban J., Bluestone J.A., Herold K.C. TCR stimulation with modified anti-CD3 mAb expands CD8T cell population and induces CD8CD25 Tregs. J Clin Invest 2005, 115(10):2904-2913.
44. Skyler J.S., Greenbaum C.J., Lachin J.M., Leschek E., Rafkin-Mervis L., Savage P., et al. Type 1 Diabetes TrialNet-an international collaborative clinical trials network. Ann N Y Acad Sci 2008, 1150:14-24.
45. Willcox A., Richardson S.J., Bone A.J., Foulis A.K., Morgan N.G. Analysis of islet inflammation in human type 1 diabetes. Clin Exp Immunol 2009, 155(2):173-181.
46. Pescovitz M.D., Greenbaum C.J., Krause-Steinrauf H., Becker D.J., Gitelman S.E., Goland R., et al. Rituximab: B-lymphocyte depletion, and preservation of beta-cell function. N Engl J Med 2009, 361(22):2143-2152.
47. Lee R.S., Rusche J.R., Maloney M.E., Sachs D.H., Sayegh M.H., Madsen J.C. CTLA4Ig-induced linked regulation of allogeneic T cell responses. J Immunol 2001, 166(3):1572-1582.
48. Barlow A.K., Like A.A. Anti-CD2 monoclonal antibodies prevent spontaneous and adoptive transfer of diabetes in the BB/Wor rat. Am J Pathol 1992, 141(5):1043-1051.
49. Gabay C., Lamacchia C., Palmer G. IL-1 pathways in inflammation and human diseases. Nat Rev Rheumatol 2010, 6(4):232-241.
50. Larsen C.M., Faulenbach M., Vaag A., Volund A., Ehses J.A., Seifert B., et al. Interleukin-1-receptor antagonist in type 2 diabetes mellitus. N Engl J Med 2007, 356(15):1517-1526.
51. Larsen C.M., Faulenbach M., Vaag A., Ehses J.A., Donath M.Y., Mandrup-Poulsen T. Sustained effects of interleukin-1 receptor antagonist treatment in type 2 diabetes. Diabetes Care 2009, 32(9):1663-1668.
52. Koulmanda M., Bhasin M., Hoffman L., Fan Z., Qipo A., Shi H., et al. Curative and beta cell regenerative effects of alpha1-antitrypsin treatment in autoimmune diabetic NOD mice. Proc Natl Acad Sci U S A 2008, 105(42):16242-16247.
53. Louvet C., Szot G.L., Lang J., Lee M.R., Martinier N., Bollag G., et al. Tyrosine kinase inhibitors reverse type 1 diabetes in nonobese diabetic mice. Proc Natl Acad Sci U S A 2008.
54. Nussbaum G., Zanin-Zhorov A., Quintana F., Lider O., Cohen I.R. Peptide p277 of HSP60 signals T cells: inhibition of inflammatory chemotaxis. Int Immunol 2006.
55. Couri C.E., Oliveira M.C., Stracieri A.B., Moraes D.A., Pieroni F., Barros G.M., et al. C-peptide levels and insulin independence following autologous nonmyeloablative hematopoietic stem cell transplantation in newly diagnosed type 1 diabetes mellitus. JAMA 2009, 301(15):1573-1579.
56. Weiner H.L. Oral tolerance: an active immunologic process mediated by multiple mechanisms. J Clin Invest 2000, 106(8):935-937.
57. Ludvigsson J., Faresjo M., Hjorth M., Axelsson S., Cheramy M., Pihl M., et al. GAD treatment and insulin secretion in recent-onset type 1 diabetes. N Engl J Med 2008, 359:1909-1920.
58. Hjorth M., Axelsson S., Ryden A., Faresjo M., Ludvigsson J., Casas R. GAD-alum treatment induces GAD(65)-specific CD4(+)CD25(high)FOXP3(+) cells in type 1 diabetic patients. Clin Immunol 2010.
59. Mahon J.L., Sosenko J.M., Rafkin-Mervis L., Krause-Steinrauf H., Lachin J.M., Thompson C., et al. The trialnet natural history study of the development of type 1 diabetes: objectives, design, and initial results. Pediatr Diabetes 2009, 10(2):97-104.
60. Skyler J.S., Brown D., Chase H.P., Collier E., Cowie C., Eisenbarth G.S., et al. Effects of insulin in relatives of patients with type 1 diabetes mellitus. New Engl J Med 2002, 346(22):1685-1691.
61. Nanto-Salonen K., Kupila A., Simell S., Siljander H., Salonsaari T., Hekkala A., et al. Nasal insulin to prevent type 1 diabetes in children with HLA genotypes and autoantibodies conferring increased risk of disease: a double-blind, randomised controlled trial. Lancet 2008, 372(9651):1746-1755.
62. Walter M., Philotheou A., Bonnici F., Ziegler A.G., Jimenez R. No effect of the altered peptide ligand NBI-6024 on beta-cell residual function and insulin needs in new-onset type 1 diabetes. Diabetes Care 2009, 32(11):2036-2040.
63. Thrower S.L., James L., Hall W., Green K.M., Arif S., Allen J.S., et al. Proinsulin peptide immunotherapy in type 1 diabetes: report of a first-in-man Phase I safety study. Clin Exp Immunol 2009, 155(2):156-165.
64. Skyler J.S. Update on worldwide efforts to prevent type 1 diabetes. Ann N Y Acad Sci 2008, 1150:190-196.
65. Nakayama M., Abiru N., Moriyama H., Babaya N., Liu E., Miao D., et al. Prime role for an insulin epitope in the development of type 1 diabetes in NOD mice. Nature 2005, 435(7039):220-223.
66. Concannon P., Rich S.S., Nepom G.T. Genetics of type 1A diabetes. N Engl J Med 2009, 360(16):1646-1654.
67. Pugliese A., Zeller M., Fernandez A., Zalcberg L.J., Bartlett R.J., Ricordi C., Pietropaolo M., Eisenbarth G.S., Bennett S.T., Patel D.D. The insulin gene is transcribed in the human thymus and transcription levels correlated with allelic variation at the INS VNTR-IDDM2 susceptibility locus for type 1 diabetes. Nat Genet. 1997, 15(3):293-297.
68. Wicklow B.A., Polychronakos C. Insulin auto-immunity: implications for the prevention of Type 1 diabetes mellitus. Exp Rev Clin Immunol 2009, 5(1):55-62.
69. Barratt B.J., Payne F., Lowe C.E., Hermann R., Healy B.C., Harold D., et al. Remapping the insulin gene/IDDM2 locus in type 1 diabetes. Diabetes 2004, 53(7):1884-1889.
70. Skyler J.S., Krischer J.P., Wolfsdorf J., Cowie C., Palmer J.P., Greenbaum C., et al. Effects of oral insulin in relatives of patients with type 1 diabetes: the diabetes prevention trial-type 1. Diabetes Care 2005, 28(5):1068-1076.
71. Virtanen S.M., Knip M. Nutritional risk predictors of beta cell autoimmunity and type 1 diabetes at a young age. Am J Clin Nutr 2003, 78(6):1053-1067.
72. Knip M., Virtanen S.M., Seppa K., Ilonen J., Savilahti E., Vaarala O., et al. Dietary intervention in infancy and later signs of beta-cell autoimmunity. N Engl J Med 2010, 363(20):1900-1908.
73. Visser J.T., Lammers K., Hoogendijk A., Boer M.W., Brugman S., Beijer-Liefers S., et al. Restoration of impaired intestinal barrier function by the hydrolysed casein diet contributes to the prevention of type 1 diabetes in the diabetes-prone BioBreeding rat. Diabetologia 2010, 53(12):2621-2628.
74. Matthews J.B., Staeva T.P., Bernstein P.L., Peakman M., von H.M. Developing combination immunotherapies for type 1 diabetes: recommendations from the ITN-JDRF Type 1 Diabetes Combination Therapy Assessment Group. Clin Exp Immunol 2010, 160(2):176-184.
75. Michels A.W., Nakayama M. The anti-insulin trimolecular complex in type 1 diabetes. Curr Opin Endocrinol Diabetes Obes 2010, 17(4):329-334.
76. Erlich H., Valdes A.M., Noble J., Carlson J.A., Varney M., Concannon P., et al. HLA DR-DQ haplotypes and genotypes and type 1 diabetes risk: analysis of the type 1 diabetes genetics consortium families. Diabetes 2008, 57:1084-1092.
77. Steenkiste A., Valdes A.M., Feolo M., Hoffman D., Concannon P., Noble J., et al. 14th International HLA and Immunogenetics Workshop: report on the HLA component of type 1 diabetes. Tissue Antigens 2007, 69(Suppl. 1):214-225.
78. Palmer J.P., Asplin C.M., Clemons P., Lyen K., Tatpati O., Raghu P.K., et al. Insulin antibodies in insulin-dependent diabetics before insulin treatment. Science 1983, 222(4630):1337-1339.
79. Achenbach P., Koczwara K., Knopff A., Naserke H., Ziegler A.G., Bonifacio E. Mature high-affinity immune responses to (pro)insulin anticipate the autoimmune cascade that leads to type 1 diabetes. J Clin Invest 2004, 114(4):589-597.
80. Lee K.H., Wucherpfennig K.W., Wiley D.C. Structure of a human insulin peptide/HLA-DQ8 complex and susceptibility to type 1 diabetes. Nat Immunol 2001, 2:501-507.
81. Stadinski B.D., Zhang L., Crawford F., Marrack P., Eisenbarth G.S., Kappler J.W., et al. T cells recognize insulin bound to IAg7 in an unexpected: weakly binding register. Proc Natl Acad Sci U S A 2010, 107(24):10978-10983.